Diagnosis of incident heart failure in the 2004-2005 era was associated with lower 6-month all-cause mortality compared to the 1995-1997 era (14% vs 26%, p<0.001).
Cohort (n=948)
Yes
Absolute Event Rate: 14% vs 26%
p-value: p=<0.001
Objective: To investigate the secular trend in survival after a new diagnosis of heart failure in the UK population. Design and Setting: Comparison of all-cause mortality in the 6 months after diagnosis of heart failure in population-based studies in the south east of England in 2004–5 (Hillingdon–Hastings Study) and 1995–7 (Hillingdon–Bromley Studies). Participants: 396 patients in the 2004–5 cohort and 552 patients in the 1995–7 cohort with incident (new) heart failure. Main Outcome Measures: All-cause mortality. Results: All-cause mortality rates were 6% (95% CI 3% to 8%) at 1 month, 11% (8% to 14%) at 3 months and 14% (11% to 18%) at 6 months in the 2004–5 cohort compared with 16% (13% to 20%), 22% (19% to 25%) and 26% (22% to 29%), respectively, in the 1995–7 cohort (difference between the two cohorts, p<0.001). The difference in survival was not explained by any difference in the demographics or severity of heart failure at presentation. There was a difference at baseline and thereafter in the use of neurohormonal antagonists (β-blockers and angiotensin-converting enzyme inhibitors). Conclusions: Although early mortality remains high among patients with newly diagnosed heart failure in the UK general population, there is strong evidence of a marked improvement in survival from 1995–7 to 2004–5, perhaps partly explained by an increased usage of neurohormonal antagonists.
Mehta et al. (Wed,) conducted a cohort in Incident (new) heart failure (n=948). Diagnosis in 2004-2005 era vs. Diagnosis in 1995-1997 era was evaluated on All-cause mortality at 6 months (p=<0.001). Diagnosis of incident heart failure in the 2004-2005 era was associated with lower 6-month all-cause mortality compared to the 1995-1997 era (14% vs 26%, p<0.001).